Advertisement
UK markets closed
  • FTSE 100

    7,963.12
    +31.14 (+0.39%)
     
  • FTSE 250

    19,899.18
    +88.52 (+0.45%)
     
  • AIM

    744.03
    +1.92 (+0.26%)
     
  • GBP/EUR

    1.1700
    +0.0031 (+0.27%)
     
  • GBP/USD

    1.2641
    +0.0003 (+0.03%)
     
  • Bitcoin GBP

    56,075.60
    +1,423.46 (+2.60%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,253.44
    +4.95 (+0.09%)
     
  • DOW

    39,786.72
    +26.64 (+0.07%)
     
  • CRUDE OIL

    82.65
    +1.30 (+1.60%)
     
  • GOLD FUTURES

    2,236.70
    +24.00 (+1.08%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,491.79
    +14.70 (+0.08%)
     
  • CAC 40

    8,209.58
    +4.77 (+0.06%)
     

3 Biotech Stocks Ripe for Spring Portfolio Cleaning

3 Biotech Stocks Ripe for Spring Portfolio Cleaning

This April, many previous growth stocks have cooled, and the biotech sector is no exception. FibroGen (NASDAQ: FGEN), Novavax (NASDAQ: NVAX), and Editas Medicine (NASDAQ: EDIT) have all taken a beating for various reasons. It usually is not a reassuring sign to see that, right before going in front of the U.S. Food and Drug Administration (FDA) for review, a company wants to clarify prior data in regards to cardiovascular safety.